Additional Value of PET-CT in Staging of Clinical Stage IIB and III Breast Cancer

Segaert, I.; Mottaghy, Felix M.; Ceyssens, Sarah; Wever, Walter De; Stroobants, Sigrid; Ongeval, Chantal Van; Limbergen, E. Van; Wildiers, Hans; Paridaens, Robert; Vergote, Ignace; Christiaens, Marie-Rose; Neven, Patrick

doi:10.1111/j.1524-4741.2010.00987.x

Cited by 106 publications

(86 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In literature, only some studies report with detail about the diagnostic accuracies of PET/CT at early diagnosis of BC [24,25,29,31,[39][40][41][42], as depicted the (Table 1).…”

Section: Early Distant Metastases Detectionmentioning

confidence: 99%

Nuclear Imaging and Early Breast Cancer Detection

Evangelista¹,

Burei²,

Cervino³

2012

J Cancer Sci Ther

View full text Add to dashboard Cite

show abstract

“…In literature, only some studies report with detail about the diagnostic accuracies of PET/CT at early diagnosis of BC [24,25,29,31,[39][40][41][42], as depicted the (Table 1).…”

Section: Early Distant Metastases Detectionmentioning

confidence: 99%

Nuclear Imaging and Early Breast Cancer Detection

Evangelista¹,

Burei²,

Cervino³

2012

J Cancer Sci Ther

View full text Add to dashboard Cite

show abstract

“…For this reason, some clinicians perform bone scintigraphy even in patients who have undergone FDG imaging. However, FDG-avid sclerotic bone metastases are often observed in breast cancer patients [38], and purely sclerotic bone metastases show osteocondensation on CT images, allowing them to be detected using the hybrid PET/CT procedure [39]. Several authors have demonstrated that PET/ CT is more accurate than scintigraphy for depiction of bone metastases [18,40,41], and a recent systematic review and meta-analysis (668 patients in total) concluded that FDG-PET/CT (sensitivity, 93 %; specificity, 99 %) performed better than bone scintigraphy (sensitivity, 81 %; specificity, 96 %) [42].…”

Section: Stagingmentioning

confidence: 99%

“…For the initial staging work-up, many conventional imaging modalities, such as X-ray mammography, MR mammography, chest plain radiography, bone scintigraphy, and breast, axillary and liver ultrasonography, have been widely utilized. In recent years, several groups have evaluated the clinical role of FDG-PET/CT for pretreatment evaluation of breast cancer in comparison with conventional imaging tools [18,39,[43][44][45][46][47][48][49][50][51][52][53][54] (Table 2). These studies revealed that FDG-PET/CT is generally helpful, but particularly valuable for detection of extra-axillary (infraclavicular, supraclavicular and internal mammary) nodal metastasis and occult distant metastasis relative to conventional modalities, especially in patients with inflammatory breast cancer [43,46,47] and stage II-III disease [18, Fig.…”

Section: Initial Stagingmentioning

confidence: 99%

Present and future role of FDG-PET/CT imaging in the management of breast cancer

Kitajima

Miyoshi

2016

Jpn J Radiol

View full text Add to dashboard Cite

by malignant cells, opened a new field in clinical oncologic imaging. Recently, integrated positron emission tomography/computed tomography (PET/CT), in which a full-ringdetector clinical PET scanner and multidetector-row helical CT scanner are combined, has made it possible to acquire both metabolic and anatomic imaging data using a single device in a single diagnostic session, and provides precise anatomic localization of suspicious areas of increased FDG uptake. When used in a clinical setting, FDG-PET/CT leads to a significant improvement in diagnostic accuracy and has had a considerable impact on patient management, including diagnosis, initial staging, optimization of treatment, restaging, monitoring of the response to therapy, and prognostication of various malignant tumors. We herein review the current and future roles of FDG-PET/CT in the management of breast cancer, discussing its usefulness and limitations for imaging in these patients. DiagnosisFDG-PET imaging has poor sensitivity (<50 %) for subcentimeter breast cancers [9,10]. This is due to the limited spatial resolution of PET and, in some cases, by tumor characteristics (e.g., low FDG avidity in grade 1 cancer, ductal carcinoma in situ, or lobular carcinoma) [1,2]. Specificity can also be altered by variations of FDG uptake in certain benign conditions, such as infection, fibroadenoma, ductal adenoma, inflammatory granulomatous mastitis, and fibrocystic changes [3].In order to improve specificity, some authors would obtain a second series of PET images centered on the breast approximately 2 h after FDG injection (dual-time imaging) [4]. Indeed, FDG uptake seems to increase with time in the case of malignancy, while some inflammatory lesions show stable or decreasing uptake [4]. However, dual-time Abstract Integrated positron emission tomography/computed tomography (PET/CT) with 2-[18F]fluoro-2-deoxyd-glucose (FDG) is a useful tool for acquisition of both glucose metabolic and anatomic imaging data using a single device in a single diagnostic session, and has opened a new field in clinical oncologic imaging. FDG-PET/CT has been used successfully for the diagnosis, initial staging, restaging, early treatment response assessment, evaluation of metastatic disease response, and prognostication of breast cancer as well as various malignant tumors. We herein review the current place and role of FDG-PET/CT in the management of breast cancer, focusing on its usefulness and limitations in the imaging of these patients.

show abstract

“…[3] Clinicians usually refer patients for PET/CT scan when conventional imaging studies are equivocal, suggestive or considered as high risk according to patient's histological and surgical manifestations. [4] FDG PET/CT may be useful for evaluating asymptomatic treated breast cancer patients with rising levels of tumor markers without clinical symptoms. In this clinical scenario, FDG PET/CT allows more accurate diagnosis of metastatic disease compared with conventional imaging.…”

Section: Introductionmentioning

confidence: 99%

PET/CT Versus CT In Post-Operative Follow Up Of Breast Cancer Patients

Mohamed¹,

Ebied²,

Hussein³

2015

IJMI

View full text Add to dashboard Cite

Abstract:Objectives: The aim of this work is to compare the sensitivity and specificity of CT alone versus PET/CT in postoperative follow up of breast cancer patients. Background: Positron emission tomography (PET), using 18F-fluorodeoxyglucose (FDG) is based on the principle of increased glucose metabolism in malignant tumors and has been frequently investigated in breast cancer. Materials & Methods: Thirty female patients with breast cancer have been investigated. All patients had positive operative history. PET/CT studies were performed for post-operative follow up. The inclusion criteria in this study are histologically proved breast cancer, positive operative history and normal blood urea and creatinine levels. Exclusion criteria is pregnancy and renal impairment. Patients were divided into three groups, first group FDG PET/CT was requested for non-conclusive CT findings, second group patients referred for FDG PET/CT for elevated tumor markers, while in third group FDG PET/CT was requested for follow up after chemotherapy and/or radiotherapy. Results: A comparison of the sensitivity and specificity for CT alone versus PET/CT in each group, in the first group CT alone had sensitivity and specificity of 90% and 12.5% respectively, while PET/CT had sensitivity and specificity 100%. In the second group CT alone had sensitivity and specificity of 57% and 100% respectively, while PET/CT had sensitivity and specificity of 100%. In group three, CT alone had sensitivity and specificity of 83.3% and 84.25%, respectively and PET/CT had sensitivity of 83.3% and specificity of 100%.Conclusions: PET/CT is more sensitive and specific than CT alone for post-operative follow up of breast cancer patients.

show abstract

Additional Value of PET-CT in Staging of Clinical Stage IIB and III Breast Cancer

Cited by 106 publications

References 23 publications

Nuclear Imaging and Early Breast Cancer Detection

Nuclear Imaging and Early Breast Cancer Detection

Present and future role of FDG-PET/CT imaging in the management of breast cancer

PET/CT Versus CT In Post-Operative Follow Up Of Breast Cancer Patients

Contact Info

Product

Resources

About